<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04998825</url>
  </required_header>
  <id_info>
    <org_study_id>NGH001</org_study_id>
    <nct_id>NCT04998825</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerability of Proteoglycan F in the Treatment of Knee Osteoarthritis</brief_title>
  <acronym>Proteoglycan</acronym>
  <official_title>Research on Efficacy and Tolerability of Proteoglycan F in the Treatment of Knee Osteoarthritis: a Prospective, Randomized, Double-blind Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Geriatric Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ichimaru Pharcos, Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Geriatric Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial study is conducted in Vietnam to assess the efficacy and tolerability of&#xD;
      Proteoglycan F in the treatment of primary knee osteoarthritis. 72 outpatients (40-80 years&#xD;
      old) were diagnosed with primary knee osteoarthritis and met the American College of&#xD;
      Rheumatology 1991 criteria. Patients have to be symptomatic for ≥ 3 months before enrollment&#xD;
      and have a radiologic grade II and III measured by the Kellgren-Lawrence criteria. The study&#xD;
      was designed as a Prospective, Randomized, Double-blind Controlled trial. Each patient will&#xD;
      be follow during 24 weeks of intervention, follow-up every 4 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With the trend of aging population and progressive increment of obesity in Vietnam, the&#xD;
      number of patients suffering from osteoarthritis most likely will substantially increase in&#xD;
      the coming years. Therefore, it is necessary to having a suitable and effective approach of&#xD;
      treatment for osteoarthritis by using functional foods.&#xD;
&#xD;
      Proteoglycan is the basic substance of articular cartilage. Proteoglycans are mostly found in&#xD;
      the extracellular matrix of animal tissue as cartilage, or in the blood vessels and brain.&#xD;
      These substances are a key ingredient in the regeneration of cartilage, inhibiting the enzyme&#xD;
      elastase - an intermediate that causes degenerative articular cartilage and reduces the&#xD;
      formation of free oxygen radicals in cartilage tissue. Therefore, the effects are on&#xD;
      inhibiting cartilage calcification, regenerating cartilage and relieving pain for cartilage&#xD;
      degeneration, promoting cartilage metabolism, forming cartilage.&#xD;
&#xD;
      Previous studies have demonstrated that proteoglycan enhances fluid not only to alleviate&#xD;
      arthritis pain but also prevent complications, as it gradually overcomes the damage of joint&#xD;
      bone, resolves inflammation, helps relieve pain and prevent osteoarthritis, osteoporosis&#xD;
      effectively. Otherwise, industrially extracted Proteoglycans presents to be safe and valuable&#xD;
      for future studies of its function. Therefore, this randomized, double-blind controlled trial&#xD;
      is conducted in Vietnam to assess the efficacy and tolerability of Proteoglycan F in the&#xD;
      treatment of primary knee osteoarthritis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain relief</measure>
    <time_frame>6 month</time_frame>
    <description>Pain intensity was assessed using the Numerical rating scale (NRS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduce symptoms of knee osteoarthritis</measure>
    <time_frame>6 month</time_frame>
    <description>Symptoms (pain, functionality and joints stiffness) were assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of balance, walking ability and functional mobility</measure>
    <time_frame>6 month</time_frame>
    <description>Assessed using the Timed Up and Go test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of knee joint cartilage thickness</measure>
    <time_frame>6 month</time_frame>
    <description>The cartilage thickness was measured using knee ultrasound</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The transverse relaxation time (T2) of the cartilage</measure>
    <time_frame>6 month</time_frame>
    <description>Assessed using Magnetic resonance imaging (MRI) of knee</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cytokine levels</measure>
    <time_frame>6 months</time_frame>
    <description>Cytokine levels (IL-1β, TNF-α levels)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related-quality of life</measure>
    <time_frame>6 months</time_frame>
    <description>Assessed using the EuroQol 5 dimensions 5 levels questionnaires (EQ-5D-5L)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <description>Any adverse events will be recorded</description>
  </other_outcome>
  <other_outcome>
    <measure>Liver enzymes</measure>
    <time_frame>6 months</time_frame>
    <description>AST, ALT</description>
  </other_outcome>
  <other_outcome>
    <measure>Kidney function</measure>
    <time_frame>6 month</time_frame>
    <description>ure, creatinine level</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma lipids</measure>
    <time_frame>6 month</time_frame>
    <description>Total cholesterol, Triglyceride, HDL-c, LDL-c</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Primary Osteoarthritis of Knee Nos</condition>
  <arm_group>
    <arm_group_label>Proteoglycan F group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Taking Proteoglycan F&#xD;
Dosage of Proteoglycan F: 50mg/day&#xD;
Used time: 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Taking Placebo (Dextrin)&#xD;
Dosage of Placebo: 50mg/day&#xD;
Used time: 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Proteoglycan F</intervention_name>
    <description>Salmon proteoglycan (Proteoglycan F) was extracted from salmon (Oncorhynchus keta) nasal cartilage. Salmon cartilage PG (Proteoglycan F) was manufactured in the form of a hard capsule by Ichimaru Pharcos, Co., Ltd. (at 318-1 Asagi, Motosu-shi, Gifu 501-0475 Japan) and consisted of 50 mg proteoglycan.</description>
    <arm_group_label>Proteoglycan F group</arm_group_label>
    <other_name>PGF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo product</intervention_name>
    <description>The placebo capsule contained only dextrin powder (Ichimaru Pharcos, Co., Ltd.).</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Dextrin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  40-80 years old&#xD;
&#xD;
          -  Diagnosed with primary knee osteoarthritis and met the American College of&#xD;
             Rheumatology 1991 criteria&#xD;
&#xD;
          -  Patients have to be symptomatic for ≥ 3 months before enrollment&#xD;
&#xD;
          -  Have a radiologic grade II and III measured by the Kellgren-Lawrence criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with secondary knee osteoarthritis&#xD;
&#xD;
          -  Patients with grade-I and IV osteoarthritis (Kellgren-Lawrence)&#xD;
&#xD;
          -  Patients having joint lavage, arthroscopy, or treatment with hyaluronic acid or other&#xD;
             disease modifying agents during the previous 6 months, or treated with intra-articular&#xD;
             corticosteroids during the past 3 months, will be excluded from the study.&#xD;
&#xD;
          -  Patients have contraindications to Non-Steroidal Anti-Inflammatory Drugs&#xD;
&#xD;
          -  Patients have hematologic disorders, renal disease, liver disease, diabetes mellitus,&#xD;
             acute illness, other rheumatic diseases, disabling comorbid conditions that would make&#xD;
             it impossible for the patient to visit the research center.&#xD;
&#xD;
          -  Pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anh T Nguyen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Geriatric Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huyen TT Vu, PhD</last_name>
    <phone>+840913531579</phone>
    <email>vuthanhhuyen11@hmu.edu.vn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thu TH Nguyen, Msc</last_name>
    <phone>+840962841944</phone>
    <email>nththu.bvlk@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Geriatric Hospital</name>
      <address>
        <city>Hanoi</city>
        <zip>100000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
    <contact>
      <last_name>Sinh V Phan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Institution of Nutrition</name>
      <address>
        <city>Hanoi</city>
        <zip>100000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/14972335/</url>
    <description>Whole-Organ Magnetic Resonance Imaging Score (WORMS) of the knee in osteoarthritis</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4973041/</url>
    <description>Evaluation of a quantitative measurement of suprapatellar effusion by ultrasonography and its association with symptoms of radiographic knee osteoarthritis: a cross-sectional observational study</description>
  </link>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/27211862/</url>
    <description>Efficacy of progressive aquatic resistance training for tibiofemoral cartilage in postmenopausal women with mild knee osteoarthritis: a randomised controlled trial</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 15, 2021</study_first_submitted>
  <study_first_submitted_qc>August 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2021</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Geriatric Hospital</investigator_affiliation>
    <investigator_full_name>Nguyen Trung Anh</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>Proteoglycan F</keyword>
  <keyword>knee osteoarthritis</keyword>
  <keyword>Vietnam</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Will individual participant data be available (including data dictionaries)?&#xD;
Yes&#xD;
What data in particular will be shared?&#xD;
-&gt;Individual participant data that underlie the results reported in this article, after deidentification (text, tables,figures, and appendices).&#xD;
What other documents will be available?&#xD;
-&gt; Study Protocol&#xD;
When will data be available (start and end dates)? --&gt; Beginning 9 months and ending 36 months following article publication.&#xD;
With whom?&#xD;
-&gt; Investigators whose proposed use of the data has been approved by an independent review committee (&quot;learned intermediary&quot;) identified for this purpose.&#xD;
For what types of analyses?&#xD;
-&gt; For individual participant data meta-analysis&#xD;
By what mechanism will data be made available?&#xD;
-&gt; Not applicable</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

